Cargando…
Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias
The paradigm for the treatment of monoclonal gammopaties has dramatically changed: therapeutic options in multiple myeloma (MM) have evolved from the introduction of melphalan and prednisone in the 1960s, high-dose chemotherapy and stem cell transplantation in the late 1980s and 1990s, to the rapid...
Autores principales: | Roccaro, Aldo M, Ghobrial, Irene M, Blotta, Simona, Treon, Steven P, Malagola, Michele, Anderson, Kenneth C, Richardson, Paul G, Russo, Domenico |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721375/ https://www.ncbi.nlm.nih.gov/pubmed/19707373 |
Ejemplares similares
-
Quantitation of Monoclonal Plasma Cells in Bone Marrow Biopsies in Plasma Cell Dyscrasia
por: Markey, G. M., et al.
Publicado: (2003) -
The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions
por: Sacco, Antonio, et al.
Publicado: (2017) -
Telomerase activity in plasma cell dyscrasias
por: Xu, D, et al.
Publicado: (2001) -
Ocular complications of plasma cell dyscrasias
por: Singh, Rohan Bir, et al.
Publicado: (2023) -
The Non-Coding RNA Landscape of Plasma Cell Dyscrasias
por: Morelli, Eugenio, et al.
Publicado: (2020)